Navigation Links
AstraZeneca and UCL to collaborate to develop regenerative medicines for diabetic retinopathy
Date:9/13/2010

AstraZeneca and UCL (University College London) today announced that they have entered into a collaboration to develop regenerative medicines for diabetic retinopathy (DR).

DR is now the most common cause of vision impairment among those of working age in Western society. The majority of patients with type 1 diabetes will develop retinopathy and about 20-30% will become blind. Moreover, a large number of patients with type 2 diabetes will develop retinopathy as their underlying disease progresses. With the global epidemic of type 2 diabetes, this predicament is set to worsen as over 438 million people are projected to suffer from diabetes and its complications by 2030.

Under the terms of the three-year agreement, AstraZeneca and scientists at the UCL Institute of Ophthalmology will collaborate to identify new therapeutic tools that can modulate the regenerative capacity of stem cells. Dr Marcus Fruttiger, UCL Institute of Ophthalmology, is leading the project and explains that, "These tools could be used either to manufacture transplantable material or to directly stimulate new cell growth in the eye to help restore or improve the vision of those with DR."

"AstraZeneca believes that regenerative medicine offers new opportunities to develop innovative, more effective and safer therapies to benefit patient health. Over the next few years, stem cell technology is likely to contribute to a measurable improvement in our ability to discover and develop candidate drugs, and to target those drugs to the right patient population through a better understanding of the disease process. We are delighted to be combining our drug hunting expertise with the pioneering research ongoing at UCL," said Alan Lamont, Director of Sciences and Technology Alliances at AstraZeneca .

Professor Pete Coffey, UCL Institute of Ophthalmology, adds: "This is a great collaborative opportunity and we're delighted to be working with AstraZeneca to explore the p
'/>"/>

Contact: Dominique Fourniol
d.fourniol@ucl.ac.uk
44-788-183-3274
University College London
Source:Eurekalert

Page: 1 2

Related medicine news :

1. AstraZeneca Pays $520 Million to Settle Seroquel Whistleblower Claims
2. Freedland Russo Announces $520 Million Settlement Against AstraZeneca
3. Gladstone and Lundbeck collaborate to study neurovascular disease
4. Anakam And Axolotl Collaborate To Deliver A Multi-Factor Authentication Platform For Santa Cruz Health Information Exchange
5. UCLA researchers, US military collaborate to open center for traumatic brain injury
6. Elsevier and InfoDesk collaborate to co-develop federated drug pipeline intelligence solution
7. Carefx to Collaborate with the Cleveland Clinic to Commercialize CCF Business Intelligence Solution
8. Two Hand Therapy Organizations Collaborate on Jam-Packed Educational Weekend
9. BCS Global and Iformata Sign Agreement to Collaborate on the PSVN Initiative to Deliver B2B Video Communications
10. PeopleStreme Collaborates with SkillSoft for Learning Management Content
11. Doctors must collaborate so that patients get full benefit of tamoxifen treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... (October 1, 2014) Despite a policy focus ... developmental disabilities, this vulnerable population continues to have ... The Journal of the American Dental Association ... and Tufts University School of Dental Medicine report ... influencing at-home oral care provided by caregivers to ...
(Date:10/1/2014)... Insuranceragents.info has released a new blog post ... for vulnerable family members. , Life insurance plans provide ... the family should always carry a life insurance policy ... rest of the family. , Clients can choose ... from temporary coverage or from a permanent policy. No ...
(Date:10/1/2014)... October 01, 2014 Phoseon Technology, the ... continues to expand the business worldwide. This rapid growth ... additional capacity for manufacturing efforts. The company has experienced ... five years and expects this growth to continue in ... technology gains worldwide adoption. , “We are very ...
(Date:10/1/2014)... DURHAM, N.C. A new genetic finding from Duke ... hostility, anxiety and depression might also be hard-wired to ... diabetes and heart disease. , An estimated 13 percent ... the genetic susceptibility, and knowing this could help them ... healthy diet, exercise and stress management. , "Genetic susceptibility, ...
(Date:10/1/2014)... NJ (PRWEB) October 01, 2014 Diet Doc ... their intentions to lose weight and their dieting attempts could ... fatty foods. Including hormone diet treatments into their ... allows patients to see fast and effective weight loss results, ... begin forming healthy habits to maintain their weight for the ...
Breaking Medicine News(10 mins):Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4
... , TUESDAY, Nov. 22 (HealthDay News) -- ,Taking ... by the brand name Tylenol) over time can lead to ... to a new study. These "staggered overdoses" can occur ... more acetaminophen than they should, explained Dr. Kenneth Simpson, author ...
... HealthDay Reporter , TUESDAY, Nov. 22 (HealthDay News) -- As ... related health problems, a new study finds. In 2009, ... reactions to beverages such as Monster and Rockstar than they ... released Tuesday. More than 13,000 ER visits related to ...
... -- Elderly black patients who require surgery for an intestinal ... the hospital than white patients, a new study has found. ... black patients had the same health insurance as white patients, ... pouches in the lining of the intestine become infected or ...
... Langone Medical Center researchers have discovered the novel protective ... study, published in the November issue of journal ... against acute pancreatitis, a sudden dangerous swelling and inflammation ... demonstrate that an abundance of dendritic cells are needed ...
... Nov. 22 (HealthDay News) --,College students tend to smoke when ... study. "Students are using social events and work as ... author, Nikole Cronk, an assistant professor of family and community ... a news release. "This research is important for those working ...
... News) -- A weakened immune system and unhealthy lifestyle habits ... cancer, according to a new study. The researchers also ... HIV infection might reduce cancer risk. The primary goal ... risk of cancer in HIV-infected patients, was to determine how ...
Cached Medicine News:Health News:Too Much Acetaminophen Over Time May Damage Liver 2Health News:ER Visits for Energy-Drink Ills Soar in U.S. 2Health News:ER Visits for Energy-Drink Ills Soar in U.S. 3Health News:More Blacks Die in Hospital After Diverticulitis Surgery 2Health News:Dendritic cells protect against acute pancreatitis 2Health News:Dendritic cells protect against acute pancreatitis 3Health News:College Students Smoke When They Party, Drink and Work 2Health News:HIV Patients at Heightened Risk for Certain Cancers 2
(Date:10/1/2014)... 2014  Varian Medical Systems (NYSE: VAR ... the fourth quarter of fiscal year 2014 following the ... The news release will be followed by a teleconference ... The news release and a link to the conference ... at: www.varian.com/investor .  To access the teleconference call ...
(Date:10/1/2014)... 2014 Quantum Materials Corp (OTCQB:QTMM) today ... photoactive quantum dots for use in next-generation ... advantages for solar power generation, the high cost ... dots with which to develop thin film solar ... utilization and acceptance. The company is also seeking ...
(Date:10/1/2014)... , Oct. 1, 2014 ... a clinical-stage biopharmaceutical company focused on cardio-renal, ... results from its 371 patient Phase 2b ... constipation-predominant irritable bowel syndrome (IBS-C).  Results from ... meaningful improvement in IBS-C symptoms for tenapanor-treated ...
Breaking Medicine Technology:Varian Medical Systems Schedules Fourth Quarter FY2014 News Release and Conference Call 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 5Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 6
... EAST RUTHERFORD, N.J., Oct. 20 Cambrex Corporation (NYSE: ... Silver Innovation Award at the 2009 CPhI Event for ... award was accepted by Dr. Jayne E. Muir (Market ... technology to a panel of judges at this important ...
... 20 Abaxis, Inc. (Nasdaq: ABAX ), a medical ... conference call to discuss its financial results for the second ... call will be at 4:15 p.m. ET on Tuesday, October ... 858-4600 to access the conference call, or can listen via ...
Cached Medicine Technology:Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Wins 2009 Silver Innovation Award 2Abaxis to Report Second Quarter Fiscal 2010 Financial Results Tuesday, October 27, 2009 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: